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Abstract
Background: Plasmodium falciparum drug resistance represents a major health problem in malaria
endemic countries. The mechanisms of resistance are not fully elucidated. Recently, an association
between putative transporter gene polymorphisms and in vitro response to chloroquine (CQ) and
quinine has been reported in culture-adapted, cloned isolates from various geographical origins.
However, this was not confirmed in another study performed on isolates from a defined region in
Thailand.
Methods:  This study tried to find an association between putative transporters gene
polymorphisms with in vitro response to CQ and pfcrt genotype in isolates originating from various
African countries. To avoid biases of parasites adaptation in culture, fresh isolates obtained from
symptomatic, malaria-infected travellers returning from Africa to France were used. Monoclonal
isolates included in the study were selected using a msp-2 fragment analysis method. In vitro
susceptibility to CQ, single nucleotide polymorphisms and microsatellite polymorphisms in pfcrt,
pfmdr1 and six putative transporter genes were established in 27 isolates and three reference
strains.
Results: Polymorphism of pfcrt at positions 76 and 220 showed a significant association with in
vitro chloroquine resistance (P < .02 and P < .05 respectively). Polymorphism of pfmdr1 at position
86 showed an equally significant association with in vitro chloroquine response (P < .05). No
association was found between SNPs or microsatellite polymorphisms of putative transporter
genes and in vitro CQR or pfcrt genotype in imported malaria isolates from Africa.
Conclusion:  The previously described association between putative transporter gene
polymorphisms and in vitro response to chloroquine (CQ) was not confirmed in the present study.
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Background
Plasmodium falciparum malaria remains one of the major
causes of morbidity and mortality in sub-Saharan Africa,
leading each year to the death of an estimated number of
1–2.7 million individuals, mostly children [1]. Chloro-
quine (CQ) resistance of P. falciparum represents today a
major health care problem in malaria endemic countries
[2]. PfCRT, a member of the drug/metabolite transporter
superfamily, was demonstrated to play a central role in
the resistance of P. falciparum to CQ [3-6]. The identifica-
tion of PfCRT and the discovery of its role in CQR were a
step by step work. Using a genetic cross, the Wel-
lems'group demonstrated that a 36 kb locus in chromo-
some 7 was linked to CQR [7,8]. Initially a first candidate
gene, cg2, comprised in that locus and thus associated to
CQR, was considered as responsible for CQR [8-10].
However further studies refuted the hypothesis [11] and
proposed another gene equally comprised in that locus,
pfcrt, as the real, though not necessarily unique, cause for
CQR. The story of cg2 is a reminder that the apparent asso-
ciation of a molecular marker with in vitro drug resistance
is not synonymous of causality. Such associations must be
verified on numerous isolates originating from various
geographical areas and further molecular studies are
required to assess the involvement of the candidate genes
in drug resistance. Other molecules, as Pgh1, a member of
the ABC transporter superfamily encoded by pfmdr1, may
contribute to CQR [12,13]. However, the implication of
pfmdr1 in CQR remains uncertain [14-16]. The mutation
at pfmdr1  Y86 may compensate deleterious pfcrt  muta-
tions or have a role in CQR by itself [17-19].
With the availability of the P. falciparum genome, a new
era in the identification of genes potentially involved in
antimalarials resistance has opened. Mu et al. reported the
association of putative transporter gene polymorphisms
with in vitro response to CQ and quinine [20]. Among 49
genes encoding putative transporters identified in P. falci-
parum, Mu et al. found nine transporters other than prod-
ucts of pfcrt and pfmdr1, including mainly putative ABC
transporters, which where associated with in vitro CQR
and/or quinine resistance. Six new genes were associated
with the CQ response from Southeast Asian isolates (G2,
G25, G47, G49, G54, G70) and three genes were associ-
ated with the CQ response from African isolates (G7, G30,
G55). A limitation of that study was that the IC50s and sin-
gle nucleotide polymorphisms (SNPs) determinations
were performed on culture-adapted cloned isolates, which
could lead to biased results due to accumulated mutations
selected by in vitro conditions. Anderson et al. studied iso-
lates from a large number of patients from a single clinic
located on the Thai-Burma border [21] and did not
observe any significant association between in vitro CQ
response and the polymorphisms of the putative trans-
porters which had been described as strongly associated
with CQR in the original study. In particular, they did not
find an association between eight of the nine studied
genes and response to eight different antimalarial drugs,
though they reported an association between G7 gene pol-
ymorphism and in vitro artesunate response. However,
these authors did not exclude that some of the studied loci
may be associated with CQR in other regions of the world.
The present study tried to reproduce Mu's data in isolates
originating from various African countries. To avoid
biases of parasites adaptation in culture, fresh isolates
obtained from symptomatic, malaria-infected travellers
returning from Africa to France were used. Furthermore,
to avoid errors due to multiple infections, monoclonal
isolates were selected by a msp-2  fragment analysis
method [22]. No association was found between putative
Table 1: Amino acid residue 76 of the pfcrt gene and chloroquine 
response phenotype of 27 P. falciparum isolates and 3 reference 
strains.
Isolatesa CI50
bCQ (nM) pfcrt K76T
Ivory Coast 1 5.3 K
Cameroon 1 13.5 K
Senegal 1 16.8 K
Senegal 2 18.8 K
Senegal 3 23.6 K
Nigeria 1 24.8 K
Congo 1 25.6 T
Madagascar 1 27.3 K
Senegal 4 33.0 K
Madagascar 2 43.4 K
Senegal 5 44.2 T
Mauritania 1 46.6 K
Ivory Coast 2 47.6 T
Madagascar 3 50.0 K
Cameroon 1 52.9 T
Mali 1 53.1 T
Togo 1 60.4 T
the Comoros Island 1 74.5 K
Mali 2 79.6 T
Ivory Coast 3 88.2 T
Ivory Coast 4 99.6 T
Benin 1 100.0 T
Ivory Coast 5 100.0 T
Mali 3 121.0 T
Cameroon 3 169.0 T
Togo 2 173.0 T
Kenya 1 219.0 T
Africa 3D7 strain 18.5 K
Indochina W2 strain 370.0 T
Cameroon FCM29 
strain
1105.0 T
aIsolates are designated by the name of their country of origin 
followed by a number.
bFifty percent inhibitory concentration values : resistance value to 
chloroquine (CQ) corresponds to IC50>100 nM.Malaria Journal 2006, 5:24 http://www.malariajournal.com/content/5/1/24
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Microsatellite allelic frequencies of pfcrt and putative transporter genes in 27 P. falciparum isolates according to pfcrt 76 allele  and chloroquine response phenotype Figure 1
Microsatellite allelic frequencies of pfcrt and putative transporter genes in 27 P. falciparum isolates according 
to pfcrt 76 allele and chloroquine response phenotype. Microsatellite allelic relative frequencies are given according to 
pfcrt K76 (wild allele, orange bars) or pfcrt K76T (mutant allele, blue bars) (Figure a, c, e, g and i), or according to inhibitory 
concentration values (IC50) for chloroquine (susceptible isolates, yellow bars; resistant isolates, green bars) (Figure b, d, f, h and 
j). The relative frequency of the various allelic forms within each haplotype subgroup is indicated. The microsatellites have 
either (AAAT)n alleles or (TA)n alleles and they are classified according to the number (n) of repeats. Figure a, b: pfcrt micros-
atellite in intron 4; Figure c, d: G7 microsatellite; Figure e, f: G25 microsatellite in intron 3; Figure g, h: G25 microsatellite in 
intron 4; and Figure i, j: G55 microsatellite. Motif 1: TAATATTATAATAT(TA)9T Motif 2: TAATAT(TA)11TMotif 3: 
TAATAT(TA)10T Motif 4: TAATAT(TA)9T.
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transporter genes polymorphisms and in vitro CQ suscep-
tibility in imported malaria isolates from Africa.
Materials and methods
Clinical isolates
Isolates were obtained from patients admitted to a
Department of Infectious and Tropical Diseases, an Emer-
gency or Intensive Care Unit of a metropolitan French
hospital with a diagnosis of P. falciparum malaria,
between January 1998 and December 2004. All patients
had returned from various countries of Africa (Table 1).
Three reference strains adapted in culture were used: the
chloroquine sensitive 3D7 line and the chloroquine
resistant W2 and FCM29 lines; 3D7 originated from
Africa, W2 from Indochina and FCM29 from Senegal.
Malaria diagnosis
Giemsa-stained thin and thick blood smears were
observed by light microscopy at a magnification of
x1,000. Microscopy was independently performed by two
experienced technicians, each time comparing their
results with the other. Cases due to species associations
including P. falciparum were not considered in the analy-
sis.
Determination of in vitro susceptibility to chloroquine
The in vitro susceptibility to chloroquine of each isolate
was determined on parasitized red blood cells taken from
the patient, using the semi-microtest method [23]. The
50% inhibitory concentration (IC50) using tritiated
hypoxanthine uptake was calculated by non-linear regres-
sion analysis.
Parasite DNA preparation
DNA was extracted from clinical isolates using QIAamp®
mini kit (Qiagen France S.A.), following manufacturer
protocols.
Clonal analysis
The number and the proportion of genotypes within iso-
lates were determined for each patient using a previously
published fragment analysis method [22]. Briefly, the
method was based on the polymorphism of the gene
encoding merozoite surface protein 2. The amplification
of a part of merozoite surface protein-2 (msp-2) gene by
polymerase chain reaction (PCR) with a fluorescent
primer, followed by capillary gel electrophoresis, was used
to discriminate alleles of different sizes. Each genotype
was characterized by the size and the area under the curve
of the peak corresponding to its msp-2  PCR products
measured during the capillary electrophoresis. This meth-
odology allowed to detect all clones accounting for more
than 1% of the whole. The description of each isolate
included the number of msp-2 genotypes, the size of the
corresponding PCR products and the proportion of each
genotype (given in percentage) within the isolate. Isolates
showing only one single peak on the capillary gel electro-
phoresis were considered as being monoclonal and
selected for the study.
Genotyping of pfcrt, pfmdr1 and putative transporter 
genes
The pfcrt domains were amplified using the following con-
ditions: 0.3 µM of each primer (Table 2), 200 µM of
dNTPs, buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1
mM MgCl2) and 2,5 U of thermus aquaticus DNA polymer-
ase (AmpliTaq GoldTM, Applied Biosystems, APPLERA
France S.A.). The samples were incubated for five minutes
at 94°C prior to 40 cycles (94°C x 40 seconds, 59°C x 40
seconds and 72°C x 40 seconds), followed by one minute
Table 2: Oligonucleotide sequences and hybridization temperatures (HT) used for genotyping transporter polymorphisms.
Genea Predicted products Position AA change Primer (sense) Primer (antisense) HT (°C)
pfcrt Putative transporter 76 K-T 5'-TTTAGGTGGAGGTTCTTG-TC-3' 5'-ATAAAGTTGTGAGTTTCGGA-3' 59
220 A-S 5'-TTATACAATTATCTCGAAGCAG-3' 5'-CATGTTTGAAAAGCATACAGGC-3' 59
pfmdr1 ABC transporter 86 N-Y 5'-AGAGAAAAAAGATGGTAACCTCAG-3' 5'-ACC-ACAAACATAAATTAACGG-3' 51
G7 (PF13-0271) ABC transporter 1390 &1 5'-GCTAAAGAAAAGGATCCGAACA-3' 5'-CAACCTTTTCTCCATTTTCAAT-3' 50
G25 (PF14-0679) Sulfate permease Intron G-A 5'-TATGGGAGGTGCTGAATGTG-3' 5'-TCGTTATCTTCGAAATTGTAGCC-3' 61
G30 (PF14-0292) GTPase Intron C-G 5'-AATTGCAAAGGGAAGGAAGG-3' 5'-TTGGGTACACGCACGTTAAG-3' 61
G49 (PF08-0078) ABC/ATPase 146 Q-E 5'-GGAAGGCATTATAGCAAACC-3' 5'-AGTCGTTTTCCCACATCCA-3' 56
1046 L-I 5'-TGAACTTATTGAGACCGGTGAA-3' 5'-ACGCACTTTTCACCTCCA-3' 56
1116 L-I 5'-TGAACTTATTGAGACCGGTGAA-3' 5'-ACGCACTTTTCACCTCCA-3' 56
G54 (PF14-0260) Membrane protein 141 Y-Y 5'-TTGGATCAGACATTACCATC-3' 5'-GGATATTGTTCCTCAAGCTCCT-3' 56
144 T-T 5'-TTGGATCAGACATTACCATC-3' 5'-GGATATTGTTCCTCAAGCTCCT-3' 56
G55 (PF14-0133) ABC transporter Intron &2 5'-ATAATGCATACATAACCTTACC-3' 5'-TCCCATTTATGTAATATGAAC-3' 51
G70 (PFL0620c) Choline transporter 105 E-K 5'-TTGATGCGTGTGTATTGATA-3' 5'-ATGTGAACCACCTTCTGGA-3' 56
aPlasmoDB (version 4) gene identifiers are shown in brackets
&1 represents a trinucleotide insertion
&2: microsatellite polymorphism located 700 bp downstream of the stop codonMalaria Journal 2006, 5:24 http://www.malariajournal.com/content/5/1/24
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at 72°C. PCR products spanning codon pfcrt 76 were ana-
lysed by restriction fragment length polymorphism
(RFLP). Eight µL of PCR products were digested by the
restriction enzyme Apo I (New England Biolabs, Beverly)
at 50°C. RFLP products were electrophoresed on 1,5 %
agarose gels and visualized under UV after staining with
ethidium bromide.
PCR products spanning codon pfcrt 220 and intron 4 asso-
ciated microsatellite were purified using a QIAquick® PCR
Purification Kit (QIAgen, France S.A.) and sequenced. The
sequencing reaction was realized using an ABI Prism® Big
Dye Terminator Cycle sequencing kit (Applied Biosys-
tems, APPLERA France S.A.) following the manufacturer
protocols. The fluorescent products were sequenced in an
ABI Prism® 3100 Genetic Analyser (Applied Biosystems,
APPLERA France S.A.) and examined with Chromas soft-
ware.
Pfmdr1  domain was amplified as previously described
[14]. Eight microliters of PCR products were digested with
NspI (New England Biolabs, Beverly) at 37°C. RFLP prod-
ucts were processed as described above.
Amplifications of a part of the seven putative transporter
genes spanning point mutations and microsatellites were
performed using the following conditions : 0.3 µM of
each primer (Table 2), 200 µM of dNTPs, buffer (50 mM
KCl, 10 mM Tris-HCl, pH 8,3, 1 mM MgCl2) and 2,5 U of
thermus aquaticus DNA polymerase (AmpliTaq GoldTM,
Applied Biosystems, APPLERA France S.A.). The samples
were incubated for five minutes at 94°C prior 40 cycles
(94°C × 40seconds, hybridization temperature x 40 sec-
onds and 72°C x 40 seconds) (see Table 2) followed by
one minute at 72°C. PCR products underwent DNA
sequencing as described above.
Data analysis
The data were entered into a database in Excel 2003 and
statistical analysis was performed using Epi Info®, version
3.3 (Centers for Disease Control, Atlanta, USA 2004). The
comparisons between polymorphisms (SNPs) and in
vitro resistance were done using Student test. P-values
<0.05 were considered significant.
Results
Isolates and sensitivity testing
During the study period, 330 isolates had successful in
vitro CQ susceptibility determination and interpretable
pfcrt  genotype. Among these, twenty-seven isolates
appeared monoclonal on the fragment analysis method
basis. CQ IC50s of selected isolates ranged from 5.36 nM
to 219 nM (Table 1). Considering usual in vitro resistance
CQ threshold, 21 isolates were susceptible (0–100 nM)
and six were resistant (>100 nM). Nine isolates had IC50
values < 40 nM, seven isolates had IC50 values between 40
and 60 nM and 11 isolates had IC50 values > 60 nM.
Pfcrt, pfmdr1 and putative transporter sequence analysis
Single nucleotide polymorphisms (SNPs) of pfcrt at posi-
tions 76 and 220 and Pfmdr1 at position 86, and varia-
tions in the microsatellite located nine bp downstream
from A220S mutation in intron 4 of pfcrt were determined
in 27 monoclonal isolates and in three reference strains
(Table 3 and Figure 1a, 1b).
SNPs of putative transporter genes in coding regions of
G49 at positions 146, 1046 and 1116, of G54 at positions
141 and 144, of G70 at position 105, in intronic regions
of G25 at position 2991 and of G30 at position 860 were
determined in the same isolates as above. Variations in
the microsatellite located in G7 at position 1390, in the
microsatellites of G25 (one in intron 3 and one in intron
Table 3: Association between polymorphims in pfmdr 1 and 5 putative transporter genes and chloroquine response phenotype and 
pfcrt 76 mutant allele of 27 P. falciparum isolates.
Gene Predicted product Position AA change Nucleotide change IC50 
aCQ pfcrt K76T
pfcrt Transporter 76 K-T AAA-ACA P<.02 -
220 A-S GCC-TCC P<.05 P<.001
pfmdr1 ABC transporter 86 N-Y AAT-TAT P<.05 P = .37
G25 Sulfate permease Intron G-A NA NA
G30 GTPase Intron - C-G P = .65 P = .9
G49 ABC/ATPase 146 Q-E CAA-GAA P = .11 P = .9
1046 K-I AAA-ATA NA NA
1116 L-I TTA-ATA P = .54 P = .19
G54 Membrane protein 141 Y-Y TAC-TAT P = .58 P = .62
144 T-T ACG-ACA P = .54 P = .63
G70 Choline 
transporter
105 E-K GAA-AAA P = .11 P = .9
aFifty percent inhibitory concentration values : resistance value to chloroquine (CQ) corresponds to IC50 > 100 nM
NA for not applicable : no SNP was found in the studied isolates and the reference strainsMalaria Journal 2006, 5:24 http://www.malariajournal.com/content/5/1/24
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4), and in the microsatellite of G55 were also determined
(Figure 1c–j).
Correlation between transporter genotypes and in vitro 
CQ susceptibility
Polymorphism of pfcrt at positions 76 and 220 showed a
significant association with chloroquine response (CQ
response and K76T, A220S, P < .02, P < .05 respectively).
Polymorphism of pfmdr1 at position 86 showed equally a
significant association with in vitro chloroquine response
(P < .05) (Table 3).
SNPs of putative transporter genes (G7, G25, G30, G49,
G54 and G70) did not show association with CQR pheno-
type in our series of 27 isolates (Table 3).
The microsatellite located nine bp downstream from
A220S mutation in intron 4 of pfcrt  showed a
(TAAA)3(TA)n polymorphism (Figure 1a, 1b). 1A single
(TAAA)3(TA)15 microsatellite type was observed in all
isolates having pfcrt 76 mutant allele. Isolates having pfcrt
76 wild allele showed various microsatellite types
excepted the (TAAA)3(TA)15 type.
In G7 gene, at 1,390 locus, two microsatellite types were
observed: (AAAT)3 and (AAAT)4 (Figure 1c, 1d). The mic-
rosatellite in intron 3 of G25 gene showed a (TA)n poly-
morphism with n ranging from eight to 23 (Figure 1e,
1f)). The microsatellite in intron 4 of G25 gene showed a
(TA)n polymorphism with n ranging from eight to 22
(Figure 1g, 1h). The microsatellite G55 gene showed a
(TAATAT(TA)nT) polymorphism with n ranging from 9 to
11 (Figure 1i, 1j). In all these putative transporter genes,
no particular type of the studied microsatellites was signif-
icantly associated with pfcrt  polymorphism or in vitro
CQR.
Discussion
It has been shown that pfcrt mutant parasites were glo-
bally present in endemic areas and that CQR mutant alle-
les could vary according to geographical origin [24-26].
Isolates originating from various African countries were
included in the present study for two reasons: first, CQR is
largely present and at comparable levels in the considered
countries [27] and second, African parasite populations
show less geographical variation in allele frequencies than
Asian or South American populations [21]. Hence, risk of
false associations in relation with parasite population
structures bias appeared to be reduced.
The number of isolates included in the present study was
relatively small in comparison of the number of falci-
parum malaria cases observed in the hospital parasitology
laboratory during the study period. Travelers returning
from Africa with a falciparum malaria attack harbor usu-
ally a mean of three circulating clones, with a range of one
to 11 clones, according to previous results [22]. Only
monoclonal isolates were included, which mostly limited
the number of studied samples. The fragment analysis
method used to enumerate the clones enabled us to work
directly on monoclonal isolates instead of using culture-
adapted cloned isolates. Thus potential bias in the IC50s
determination was avoided.
In the present series, 15 isolates out of 27 had the pfcrt 76
mutant genotype, though only six were classified as in
vitro CQR (IC50s > 100 nM). These proportions were not
surprising as it has previously shown that pfcrt K76T was
found occasionally in isolates having CQ IC50  values
located between 40 and 60 nM and almost constantly in
isolates >60 nM [28]. These previous results were in
favour of the hypothesis that CQR could result from a
multi-gene process, pfcrt mutations being necessary but
not sufficient to acquire CQR. The present study did not
invalidate this hypothesis, but it failed to show the new
putative transporter genes polymorphisms as associated
with CQR. This could be due to the limited number of
included isolates. However, an association between pfcrt
and pfmdr1 and in vitro CQR was found in our series. In
addition, these results were consistent with those of
Anderson et al. who included numerous isolates (albeit
originating from an unique geographic area) [21].
Microsatellite polymorphisms have been demonstrated as
associated with resistant haplotypes [24]. Genome wide
microsatellite scanning has shown marked linkage dise-
quilibrium around pfcrt  locus indicating four distinct
founder events, with one ancestral mutant originating in
Asia and subsequently invading Africa. Interestingly Pfcrt
intron 4 contains a polymorphic (TAAA)n(TA)m micros-
atellite, with a particular type (TAAA)3(TA)15 found as
strongly associated with pfcrt resistant allele in a previous
study (data not shown) and also in the present series. No
association was found between the microsatellite poly-
morphisms and the SNPs of the studied putative trans-
porter genes or with in vitro CQR.
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